
Long-term survival rates for immunotherapies could be misinterpreted
Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards
Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards